CDH2 and breast cancer: This EMT phenotype induced by CPT1C in vitro was further supported by an in vivo observation as a slight to moderate positive correlation between CPT1C and the EMT markers (CPT1C vs. E-Cadherin, R=-0.17, P<0.0001; CPT1C vs. N-Cadherin, R=0.13, P<0.0001; CPT1C vs. Vimentin, R=0.37, P<0.0001; CPT1C vs. Fibronectin, R=0.23, P<0.0001; Figure 3B) was found in breast cancer patients.